Canine Congestive Heart Failure Study Guide

Overview and Clinical Importance

Congestive heart failure (CHF) is a clinical syndrome that occurs when the heart can no longer pump sufficient blood to meet the body's metabolic demands, or can only do so at elevated filling pressures. In dogs, CHF most commonly results from myxomatous mitral valve disease (MMVD), accounting for approximately 75% of all canine heart disease cases. The second most common cause is dilated cardiomyopathy (DCM), which predominantly affects large and giant breed dogs. Understanding the pathophysiology, clinical presentation, diagnostic approach, and treatment of CHF is essential for NAVLE success and clinical practice.

Heart failure in dogs carries significant morbidity and mortality. Approximately 10% of dogs presented to primary care veterinary practices have heart disease, making cardiovascular conditions a major component of the NAVLE examination. Early recognition and appropriate staging of heart disease directly impacts treatment decisions and patient outcomes.

Pathophysiology of Congestive Heart Failure

Hemodynamic Basis

Heart failure develops when cardiac output becomes insufficient to meet tissue oxygen demands. The failing heart triggers compensatory mechanisms including:

• Renin-Angiotensin-Aldosterone System (RAAS) activation: Causes sodium and water retention, vasoconstriction, and cardiac remodeling
• Sympathetic nervous system activation: Increases heart rate and contractility but also increases myocardial oxygen demand
• Cardiac remodeling: Chamber dilation and hypertrophy that initially maintains output but eventually becomes maladaptive
• Natriuretic peptide release: Counterregulatory mechanism attempting to promote natriuresis and vasodilation

Left-Sided vs. Right-Sided Heart Failure

Understanding the anatomic basis of CHF helps predict clinical signs and guides diagnostic interpretation.

Figure 1 - Lateral thoracic radiograph of a dog with left-sided CHF showing cardiomegaly with left atrial enlargement, dorsal elevation of the trachea, and perihilar pulmonary edema pattern. (A). cardiogenic pulmonary edema due to severe mitral regurgitation and (B) body of the left atrium almost touching the spine. Courtesy of Dr. Mark D. Kittleson. Accessed from https://www.merckvetmanual.com/multimedia/image/congestive-heart-failure-dog-radiograph

ACVIM Staging System for Heart Disease

The American College of Veterinary Internal Medicine (ACVIM) consensus guidelines provide a standardized staging system that guides treatment decisions. This staging system is adapted from human medicine and is essential knowledge for the NAVLE.

Common Causes of Canine CHF

Myxomatous Mitral Valve Disease (MMVD)

MMVD is the most common acquired heart disease in dogs, accounting for approximately 75% of canine cardiovascular disease. It is characterized by progressive myxomatous degeneration of the mitral valve leaflets, causing mitral regurgitation.

Breed Predispositions

• Cavalier King Charles Spaniel: Highest prevalence, often develops at younger age (may have murmur by 1-2 years)
• Other small breeds: Miniature Poodle, Chihuahua, Miniature Schnauzer, Cocker Spaniel, Dachshund, Yorkshire Terrier
• Age: Prevalence increases with age; up to 85% of small breed dogs show evidence by 13 years
• Sex: Males affected 1.5 times more commonly than females

Clinical Findings

• Murmur: Left apical systolic murmur, grade increases with disease severity
• Radiography: Left atrial enlargement (dorsal deviation of trachea, splaying of mainstem bronchi), left ventricular enlargement, pulmonary venous distension
• Echocardiography: Thickened, prolapsing mitral valve leaflets; mitral regurgitation on color Doppler; LA/Ao ratio greater than or equal to 1.6 indicates significant enlargement

Figure 2 - Echocardiogram showing mitral valve regurgitation with color Doppler flow and left atrial enlargement in a dog with MMVD. Image credit: https://todaysveterinarypractice.com/cardiology/congestive-heart-failure-in-dogs/

Dilated Cardiomyopathy (DCM)

DCM is characterized by progressive loss of myocardial contractility with ventricular dilation and wall thinning. It predominantly affects large and giant breed dogs and carries a more guarded prognosis than MMVD.

Breed Predispositions

• Double screening: Echo AND Holter annually starting at age 3
• Double trouble: VPCs greater than 300/24hr OR 50-300 on two consecutive readings = diagnostic
• Double-digit survival: Only 3-6 months median survival after CHF develops

Diagnostic Approach

Physical Examination

• Auscultation: Murmur grade and location, arrhythmias, gallop sounds, pulmonary crackles
• Respiratory assessment: Rate, effort, orthopnea, cyanosis
• Pulse quality: Weak pulses suggest low output; pulse deficits indicate arrhythmia
• Jugular assessment: Distension or pulsations indicate right-sided failure

Thoracic Radiography

Radiography is the primary diagnostic tool for confirming CHF and is essential for staging.

Radiographic Signs of Left-Sided CHF

• Cardiomegaly: Increased VHS, loss of waist, increased sternal contact
• Left atrial enlargement: Dorsal elevation of trachea and carina, splaying of mainstem bronchi
• Pulmonary venous distension: Veins larger than accompanying arteries
• Pulmonary edema: Perihilar to caudodorsal distribution, interstitial to alveolar pattern

Figure 3 – VHS (moderate cardiomegaly in a dog with a VHS of 11.5) measurement technique on lateral thoracic radiograph demonstrating how to measure the long and short axis of the heart and compare to vertebral bodies starting at T4.

Reference and image credit: https://vetmed.illinois.edu/2022/07/06/evaluating-the-heart-size-on-radiographs/

Echocardiography

Echocardiography is the gold standard for diagnosing underlying cardiac disease and assessing severity.

Treatment of Congestive Heart Failure

Emergency Management of Acute CHF

Dogs presenting in acute respiratory distress require immediate stabilization. Minimize stress - even handling for diagnostics can be fatal in severely compromised patients.

Initial Stabilization Protocol

• Oxygen supplementation: Flow-by, oxygen cage, or nasal cannula
• Furosemide IV bolus: 2-4 mg/kg IV or IM; repeat every 30-60 minutes until respiratory rate decreases
• Furosemide CRI (alternative): 0.66-1 mg/kg/hour IV
• Pimobendan: 0.25-0.3 mg/kg PO; onset of action within 1 hour
• Sedation if needed: Butorphanol 0.2-0.4 mg/kg IV or IM for anxiety/dyspnea

Chronic Management - Drug Therapy

• F = Furosemide (loop diuretic)
• A = ACE inhibitor (enalapril/benazepril)
• P = Pimobendan (inodilator)
• S = Spironolactone (aldosterone antagonist)

Refractory Heart Failure (Stage D)

When standard therapy fails, escalation strategies include:

• Increase furosemide frequency: q8h or even q6h dosing
• Switch to torsemide: More potent loop diuretic with better bioavailability; dose at approximately 10% of furosemide dose
• Add hydrochlorothiazide: 0.5-1 mg/kg PO q24h for sequential nephron blockade
• Sildenafil: 1-2 mg/kg PO q8-12h for pulmonary hypertension
• Increase pimobendan: Off-label doses up to 0.4 mg/kg TID have been used safely

Prognosis and Survival

Landmark Clinical Trials

EPIC Study (2016)

• Population: 360 dogs with Stage B2 MMVD
• Intervention: Pimobendan vs. placebo
• Result: Median 15-month delay in onset of CHF with pimobendan
• Clinical significance: Changed standard of care - pimobendan now indicated for Stage B2

QUEST Study

• Finding: Pimobendan superior to benazepril alone for Stage C MMVD

BESST Trial

• Finding: Adding spironolactone to ACE inhibitor improves outcomes

PROTECT Study

• Finding: Pimobendan delays CHF onset by approximately 9 months in preclinical Doberman DCM